1. ¹University of Michigan Medical Center, Ann Arbor, Michigan
2. ²Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois
3. ³Novartis Pharmaceuticals, East Hanover, New Jersey
4. ⁴University of Goteborg, Department of Medicine, Goteborg, Sweden
5. ⁵Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina
6. ⁶the State University of New York Downstate College of Medicine, Brooklyn, New York

Correspondence: Dr. Kenneth Jamerson, University of Michigan Health System, Department of Internal Medicine, Division of Cardiovascular Medicine, 1500 E. Medical Center Drive/3918 Taubman Center, Ann Arbor, MI 48109-0356 E-mail: jamerson@umich.edu

Received 8 December 2003; Accepted 28 May 2004.

Abstract

Reducing blood pressure (BP) to target levels is a major priority in preventing clinical events in hypertension. Typically this requires more than one drug, and recent guidelines on hypertension management therefore recommend starting with combination treatment in many patients. Diuretics have often been part of such therapy, usually paired with angiotensin converting enzyme (ACE) inhibitors or similar agents; but calcium channel blockers are also highly efficacious in reducing BP when combined with ACE inhibitors. In addition, these drug classes, separately and in combination, appear to have vasculoprotective properties. Because the primary goal of treating hypertension is to enhance survival and reduce cardiovascular outcomes, the Rationale and Design of Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial is designed as the first blinded and randomized study to prospectively compare the effects on these endpoints of two antihypertensive combinations, benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg) and amlodipine besylate/benazapril (force titrated to 5/40 mg). The doses can be further titrated to 40/25 mg or 10/40 mg, and other classes of drugs can be added as needed for optimal BP control. The primary study endpoint is a composite of cardiovascular mortality and morbidity. The study will be performed in hypertensive patients (systolic BP 160 mm Hg or currently on antihypertensive therapy) with risk factors for cardiovascular events (prior events, target organ damage, kidney disease, or diabetes). A total of 6300 subjects will be randomized to each group with the expectation that a total of 1642 primary endpoints will occur during a 5-year period, providing 90% power to detect the 15% relative reduction in events ( = 0.05) hypothesized to favor the amlodipine besylate/benazapril group. The ACCOMPLISH study will be performed in the United States and Europe. The first patient was randomizedduring 2003, and the trial should conclude in 2008.